AN2 Therapeutics says oral AN2-502998 clears T. cruzi in primate study, supports Phase 2 in chronic Chagas disease

• AN2 Therapeutics reported positive enabling data for oral AN2-502998, supporting advancement into a Phase 2 study for chronic Chagas disease.
• Results have already been presented from a nonhuman primate study showing parasite elimination that persisted for months post-treatment.
• A completed Phase 1 first-in-human study indicated the drug was generally well tolerated, supporting continued development.
• The company plans to start a Phase 2 proof-of-concept trial late this year, targeting adults with chronic infection.
• The program aims to address a market with no FDA-approved adult treatment, positioning AN2-502998 as a potential first-in-class option.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AN2 Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260604006839) on June 04, 2026, and is solely responsible for the information contained therein.